Buprenorphine and Vepdegestrant: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Vepdegestrant
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect your heart's rhythm in a similar way. Buprenorphine (a pain or opioid-treatment medicine) and vepdegestrant (a cancer medicine) can each stretch out a part of the heartbeat called the QT interval. When you take them together, that effect can add up and, in rare cases, lead to a dangerous irregular heartbeat.
This concern is based on how the drugs work rather than a lot of real-world reports, but it is taken seriously. The good news is your care team can manage this by checking heart tracings (ECGs) and keeping an eye on your body's minerals. Please don't stop either medicine on your own, just talk with your doctor or pharmacist.
Effect: Additive QTc prolongation with increased risk of torsade de pointes, polymorphic VT, and other serious arrhythmias.
Mechanism: Both agents independently prolong the QT interval; combined use produces additive PD effect. Neither is a prodrug relevant to this interaction. Evidence is theoretical; severity graded major; onset unspecified.
Management:
- Avoid concomitant use when possible.
- If unavoidable, obtain baseline and on-treatment ECGs; monitor K+ and Mg++.
- QTc >480 ms or >60 ms rise: withhold vepdegestrant, correct reversible causes, resume same dose with more frequent ECGs.
- QTc >500 ms: withhold; if no reversible cause, resume at reduced dose; discontinue if recurs.
- Discontinue vepdegestrant permanently if torsade/arrhythmia occurs.
What happens
An increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmia symptoms
Interaction Deep Dive
Do not administer vepdegestrant together with other agents recognized as having the capacity to lengthen the QTc interval, since doing so can produce a larger rise in the QTc interval along with adverse reactions tied to QTc prolongation, such as torsade de pointes, additional serious arrhythmias, and sudden death. When such combined use cannot be prevented, ECGs should be obtained at the start of and throughout concomitant treatment, as well as whenever clinically warranted. For patients whose QTc exceeds 480 ms or rises more than 60 ms above baseline (while remaining less than or equal to 500 ms): hold vepdegestrant until the QTc falls to 480 ms or below and is no more than 60 ms over baseline. Correct reversible contributors (for example, hypokalemia, hypomagnesemia) and then restart vepdegestrant at the identical dose. Begin monitoring ECGs more often. For patients with a QTc above 500 ms: withhold vepdegestrant until the QTc reaches 480 ms or lower and is less than 60 ms above baseline. Should a reversible cause be found and fixed, resume vepdegestrant at the same dose; if no reversible cause is found, resume at a lowered dose. Increase the frequency of ECG monitoring, and if a QTc greater than 500 ms occurs again, permanently stop vepdegestrant. In patients who experience torsade de pointes, polymorphic ventricular tachycardia, or symptoms of serious arrhythmia: permanently discontinue vepdegestrant1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Your care team usually prefers to avoid using these two together when possible. If both are needed, they can manage it safely with monitoring.
- Expect ECG (heart tracing) checks when starting and during treatment.
- Your team may check and correct blood minerals like potassium and magnesium, which affect heart rhythm.
- The vepdegestrant dose may be paused, adjusted, or individualized based on your ECG results.
Keep taking both medicines exactly as prescribed unless told otherwise. Tell your doctor or pharmacist about any dizziness, fainting, or palpitations, and mention all other medicines you take, since some also affect QT.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Buprenorphine and Vepdegestrant together?
Buprenorphine and vepdegestrant can each prolong the QT interval, and combining them may add up and raise the risk of a dangerous heart rhythm. Your care team will often avoid this pairing or monitor you with ECGs and manage the vepdegestrant dose closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Vepdegestrant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Vepdegestrant interaction managed?
Your care team usually prefers to avoid using these two together when possible. If both are needed, they can manage it safely with monitoring. Expect ECG (heart tracing) checks when starting and during treatment. Your team may check and correct blood minerals like potassium and magnesium, which affect heart rhythm. The vepdegestrant dose may be paused, adjusted, or individualized based on your ECG… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Vepdegestrant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VEPPANU oral tablet, vepdegestrant oral tablet. Pfizer Inc. New York, NY, 2026. DailyMed
Keep reading about Buprenorphine
Keep reading about Vepdegestrant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist